Pyxis Oncology, Inc. Net Fee Amt
Pyxis Oncology, Inc. (PYXS) had Net Fee Amt of $17.76 thousand as of 2026-08-20, per its S-3 filed 2026-08-20.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-20
- 2026-08-20: Net Fee Amt $17.76K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-20 | $17.76K S-3 · filed 2026-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |